Ruxolitinib at a concentration of 100 nM was low enough not to induce cell death, but was sufficient to exert molecular responses in MPN cell lines with inhibition of the JAK/STAT pathway. The gene discussed is SOAT1; the disease is myeloproliferative disorder.